LD-2 disclosure · 2nd Quarter - Report
KEMPHARM, INC.
Client
- Name
- KEMPHARM, INC.
- Description
- Pharmaceutical company engaged in the discovery and development of proprietary prodrugs
- Location
- Iowa · United States of America
Registrant
- Description
- Law firm
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
2 issuesPharmacy
FDA regulation of opioid abuse deterrent formulations H.R. 2430 (FDA Reauthorization Act of 2017), provisions relating to drugs H.R. 2025 (Abuse-Deterrent Opioids Plan for Tomorrow Act of 2017), all provisions
LobbyistsPHILIP ENGLISH · mr NORMAN FREDERICK LENT iii
TargetedSENATE · HOUSE OF REPRESENTATIVES · Vice President of the U.S. · White House Office · Office of Natl Drug Control Policy (NDCP) · Health & Human Services, Dept of (HHS)
Health Issues
Prodrug therapies and improving abuse deterrence and consumer safety Anti-opioid abuse legislation
LobbyistsPHILIP ENGLISH · mr NORMAN FREDERICK LENT iii · SONJA NESBIT
TargetedSENATE · HOUSE OF REPRESENTATIVES · Vice President of the U.S. · White House Office · Office of Natl Drug Control Policy (NDCP) · Health & Human Services, Dept of (HHS)